When used for the treatment of pancreatic cancer, the peptide can be broken by MMP-2 response to first release PFD to alleviate the interstitial fibrosis of pancreatic cancer tumor microenvironment, after which the GEM-encapsulated targeting liposomes can better enter the deep tumor layer to act, thus effectively improving the therapeutic effect of pancreatic cancer. This evidence concerns the gene MMP2 and neoplasm.